A 60 year old person old person is suffering from diabetes for last 10 years. a.List the biochemical investigations you should advise him as a part of regular check-up. b.Write down the biochemical reference range of those parameters. c.Explain the alternation of lipid metabolism in diabetes.
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from the textbooks. Let me compile the complete, detailed answer.
Biochemical Investigations for a 60-Year-Old with 10 Years of Diabetes
a. Biochemical Investigations for Regular Check-Up
A long-standing diabetic patient requires monitoring in three broad domains: glycemic control, diabetic complications, and cardiovascular risk factors.
1. Glycemic Control
| Investigation | Purpose |
|---|---|
| Fasting Plasma Glucose (FPG) | Day-to-day glycemic status |
| Postprandial Plasma Glucose (2-hr PPG) | Assess post-meal glucose excursions |
| HbA1c (Glycated Haemoglobin) | Average glycemic control over 8-12 weeks |
| Fructosamine / Glycated Albumin | Short-term glycemic control (2-3 weeks), useful when HbA1c is unreliable (e.g., haemolytic anaemia) |
2. Renal Function (Diabetic Nephropathy Screening)
| Investigation | Purpose |
|---|---|
| Urine Microalbuminuria (UAE) | Earliest marker of diabetic nephropathy |
| Urine Albumin-to-Creatinine Ratio (UACR) | Quantifies microalbuminuria |
| eGFR (Estimated Glomerular Filtration Rate) | Assesses kidney function |
| Serum Creatinine & BUN (Blood Urea Nitrogen) | Overall renal function |
| Serum Electrolytes (Na+, K+, Cl-) | Especially K+ in those on ACE inhibitors/ARBs |
3. Lipid Profile (Cardiovascular Risk)
| Investigation | Purpose |
|---|---|
| Total Cholesterol | CVD risk assessment |
| LDL Cholesterol | Primary target for statin therapy |
| HDL Cholesterol | Protective factor (usually decreased in DM) |
| Triglycerides (TG) | Elevated in insulin resistance |
| Non-HDL Cholesterol | Includes all atherogenic particles |
4. Liver Function
| Investigation | Purpose |
|---|---|
| Liver Function Tests (AST, ALT, ALP, GGT) | Screen for metabolic dysfunction-associated steatotic liver disease (MASLD), which is common in type 2 DM |
| Serum Albumin | Nutritional status and hepatic synthetic function |
5. Thyroid Function
| Investigation | Purpose |
|---|---|
| TSH (Thyroid Stimulating Hormone) | Hypothyroidism is common in diabetics and worsens lipid profile and glucose control |
| Free T4 | If TSH is abnormal |
6. Urine Examination
| Investigation | Purpose |
|---|---|
| Urine Routine & Microscopy | Detect glycosuria, proteinuria, ketonuria, UTI |
| Urine Ketones | Especially in poorly controlled or Type 1 DM |
7. Haematological
| Investigation | Purpose |
|---|---|
| Complete Blood Count (CBC) | Anaemia (which affects HbA1c reliability), infection |
| Serum Magnesium | Hypomagnesaemia is common in DM and worsens insulin resistance |
| Serum Vitamin B12 | Depleted by long-term metformin use |
(Sources: Tietz Textbook of Laboratory Medicine 7th Ed., p. 1736; Quick Compendium of Clinical Pathology 5th Ed., p. 33)
b. Biochemical Reference Ranges
Glycemic Parameters
| Parameter | Normal / Target in Diabetes |
|---|---|
| Fasting Plasma Glucose | Normal: 70-99 mg/dL (3.9-5.5 mmol/L) |
| Prediabetes (IFG): 100-125 mg/dL (5.6-6.9 mmol/L) | |
| Diabetes: ≥ 126 mg/dL (≥ 7.0 mmol/L) | |
| 2-hr Post-load Glucose (OGTT) | Normal: < 140 mg/dL; IGT: 140-199 mg/dL; Diabetes: ≥ 200 mg/dL |
| HbA1c | Normal: < 5.7% (< 39 mmol/mol) |
| Target in known diabetic: < 7.0% (< 53 mmol/mol) | |
| Diabetes diagnosis: ≥ 6.5% |
Renal Parameters
| Parameter | Reference Range |
|---|---|
| Serum Creatinine | Males: 0.74-1.35 mg/dL; Females: 0.59-1.04 mg/dL |
| BUN | 7-20 mg/dL |
| eGFR | ≥ 60 mL/min/1.73 m² (normal kidney function) |
| Urine Albumin (spot UACR) | Normal: < 30 mg/g creatinine |
| Microalbuminuria: 30-300 mg/g (annual screening mandatory) | |
| Macroalbuminuria: > 300 mg/g |
Lipid Profile
| Parameter | Optimal / Target Range |
|---|---|
| Total Cholesterol | Desirable: < 200 mg/dL |
| LDL Cholesterol | Target in DM (high CV risk): < 70 mg/dL |
| HDL Cholesterol | Males: > 40 mg/dL; Females: > 50 mg/dL |
| Triglycerides | Normal: < 150 mg/dL; High: ≥ 200 mg/dL |
| Non-HDL Cholesterol | Target in DM: < 100 mg/dL |
Other Parameters
| Parameter | Reference Range |
|---|---|
| TSH | 0.4-4.0 mIU/L |
| Serum Magnesium | 1.7-2.2 mg/dL |
| Serum Vitamin B12 | 200-900 pg/mL |
| ALT | 7-56 U/L |
| AST | 10-40 U/L |
(Sources: Tietz Textbook of Laboratory Medicine 7th Ed.; Quick Compendium of Clinical Pathology 5th Ed.)
c. Alterations of Lipid Metabolism in Diabetes
Diabetes mellitus produces a characteristic pattern of dyslipidaemia driven mainly by insulin deficiency or resistance. The three hallmark abnormalities are:
1. Elevated Triglycerides (Hypertriglyceridaemia)
2. Reduced HDL Cholesterol
3. Increased small, dense LDL particles
This triad is sometimes called "diabetic dyslipidaemia" or the "atherogenic lipid triad."
Mechanism 1 - Insulin Resistance and Increased Free Fatty Acid (FFA) Flux
In Type 2 DM, insulin resistance impairs the anti-lipolytic action of insulin on adipose tissue. Normally, insulin suppresses hormone-sensitive lipase (HSL) in adipocytes, preventing triglyceride breakdown. When insulin signalling fails:
- Lipolysis is unrestrained → increased release of free fatty acids (FFAs) and glycerol into the portal circulation.
- Elevated FFAs are taken up by the liver, where they serve as substrate for de novo lipogenesis and VLDL-TG synthesis.
- The liver overproduces VLDL particles, which are rich in triglycerides.
"As a result of insulin resistance in adipose tissue, lipolysis and free fatty acid flux from adipocytes are increased and efficiently cleared by liver, leading to increased very-low-density lipoprotein (VLDL)-triglyceride synthesis in hepatocytes and secretion from liver. This is also responsible for the dyslipidaemia found in type 2 DM (elevated triglycerides, reduced HDL, and increased small dense LDL particles)."
- Harrison's Principles of Internal Medicine, 22nd Ed.
Mechanism 2 - Impaired Lipoprotein Lipase (LPL) Activity
- Insulin normally stimulates lipoprotein lipase (LPL) in adipose tissue and muscle capillaries, the enzyme responsible for clearing triglycerides from chylomicrons and VLDL.
- In insulin-deficient or insulin-resistant states, LPL activity is reduced → impaired clearance of VLDL and chylomicrons → hypertriglyceridaemia.
- In severe insulin deficiency (Type 1 DM, DKA), chylomicrons accumulate producing severe hypertriglyceridaemia and even lipaemia retinalis or pancreatitis.
(Source: Guyton & Hall Textbook of Medical Physiology)
Mechanism 3 - Reduced HDL Cholesterol
- Elevated VLDL and increased triglyceride transfer to HDL particles (via cholesteryl ester transfer protein, CETP) depletes HDL of its cholesteryl ester content.
- This produces HDL particles rich in triglycerides that are rapidly catabolised by hepatic lipase → reduced HDL-C levels.
- Lower HDL means reduced reverse cholesterol transport - a key atheroprotective mechanism is compromised.
Mechanism 4 - Formation of Small Dense LDL (sdLDL)
- The same CETP-mediated triglyceride enrichment that affects HDL also affects LDL particles.
- Triglyceride-enriched LDL are acted upon by hepatic lipase, producing small, dense LDL (sdLDL) particles.
- sdLDL is particularly atherogenic because:
- It penetrates the arterial wall more easily
- It has lower affinity for LDL receptors (prolonged circulation time)
- It is more susceptible to oxidation
- Total LDL-C may appear normal, but the particle quality is much more atherogenic.
Mechanism 5 - Increased Hepatic Lipogenesis (De Novo Lipogenesis)
- Persistent hyperglycaemia activates carbohydrate response element-binding protein (ChREBP) and SREBP-1c in the liver.
- These transcription factors upregulate fatty acid synthesis enzymes (fatty acid synthase, acetyl-CoA carboxylase).
- The result is increased triglyceride synthesis and, if lipid is retained in hepatocytes, the development of non-alcoholic/metabolic dysfunction-associated steatotic liver disease (MASLD).
Summary Table of Lipid Alterations in Diabetes
| Lipid Parameter | Change in DM | Primary Mechanism |
|---|---|---|
| Triglycerides (VLDL-TG) | Increased ↑↑ | ↑ FFA flux to liver + ↓ LPL activity |
| HDL Cholesterol | Decreased ↓ | CETP-mediated TG enrichment + hepatic lipase catabolism |
| LDL Cholesterol | Normal or mildly elevated | sdLDL predominance despite normal total LDL |
| Chylomicrons | Increased ↑ (in severe DM) | ↓ LPL activity → impaired clearance |
| Free Fatty Acids | Increased ↑ | ↑ Lipolysis due to insulin resistance |
| Hepatic VLDL secretion | Increased ↑ | ↑ FFA substrate + insulin resistance |
(Sources: Harrison's Principles of Internal Medicine 22nd Ed.; Guyton & Hall Textbook of Medical Physiology; Tietz Textbook of Laboratory Medicine 7th Ed.)
Clinical Significance
The diabetic dyslipidaemia pattern substantially increases the risk of atherosclerotic cardiovascular disease (ASCVD). This is why annual lipid screening is mandatory in all diabetic patients, and why statins (targeting LDL) combined with fibrates (targeting TG) are often used. The ADA Standards of Medical Care recommend LDL < 70 mg/dL as the target for high-cardiovascular-risk diabetics, with HbA1c < 7% as the glycaemic target for most adults.
This is a shared conversation. Sign in to Orris to start your own chat.